Business
MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
CHICAGO, May 15, 2025--MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
About this update from Maia Biotechnology, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1000,"height":380,"url":"https://media.zenfs.com/en/business-wire.com/34171b88b4353c46d8ba8efb35ce4f97"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UxGhYaiR8EJu0HLrdveYTQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM2NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/34171b88b4353c46d8ba8efb35ce4f97","width":960,"height":365},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/fMry6QsXQtmeoBUeFN8p1w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwMDA7aD03NjA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/34171b88b4353c46d8ba8efb35ce4f97","width":1000,"height":380}},"lazy":false},{"type":"text","content":"CHICAGO, May 15, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that an abstract about the efficacy data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3, 2025, in Chicago, Illinois. The poster is scheduled for presentation on May 31, 2025, from 01:30pm to 04:30pm CDT in the Lung Cancer track.","length":575,"tagName":"p"},{"type":"text","content":""We continue to believe that our telomere targeting agent ateganosine (THIO) could become a best-in-class anticancer treatment with the potential to challenge the standard of care for NSCLC," said MAIA CEO Vlad Vitoc, M.D. "Treatment with ateganosine has shown excellent efficacy in third-line NSCLC to date and we look forward to presenting our findings at ASCO 2025 on May 31st."","length":401,"tagName":"p"},{"type":"text","content":"Poster Presentation Details","length":27,"tagName":"p"},{"type":"text","content":"Poster title: "Phase 2 Study of Telomere-Targeting Agent THIO Sequenced With Cemiplimab in Third-Line Immune Checkpoint Inhibitor–Resistant Advanced NSCLC: Evaluation of Overall Survival"","length":197,"tagName":"p"},{"type":"text","content":"Session date and time: May 31, 2025, 01:30pm to 04:30pm CDT","length":59,"tagName":"p"},{"type":"text","content":"Presenter: Tomasz Jankowski, M.D.","length":33,"tagName":"p"},{"type":"text","content":"M...